IMDX Steps Toward the Finish Line as GraftAssureDx Nears FDA Authorization

A 3-point stance: In-house kidney transplant rejection testing gains momentum as the company lines up regulatory clarity, Medicare tailwinds, and a reinvigorated Bio-Rad partnership.

IMDX · Earnings Call · 2026-08-10

A Regulated Product Comes Into View

Insight Molecular Diagnostics (IMDX) is at the inflection point every development-stage diagnostics company dreams about: line of sight to regulatory approval. As CEO Josh Riggs put it, “It feels great to be coming to you today with line of sight on expected FDA marketing authorization for GraftAssureDx.” — Joshua Riggs, Chief Executive Officer · 2026-08-10 The company is in the latter stages of the Class II review process, having received an additional information letter from the FDA in July. Rather than viewing the back-and-forth as a setback, management is framing it as routine—and they're taking proactive steps by scheduling an SIR meeting to align on the data package. As Riggs noted in Q&A, “Any time you get questions, there's some interpretation that's possible there on the best way to respond to them. I think the SIR meeting is just an opportunity for us to make sure that we're 100% aligned with the FDA before we package up this additional data and hit the submit button.” — Joshua Riggs, Chief Executive Officer · 2026-08-10 This is a classic de-risking moment. The company has tripled its sample collection since March and feels good about addressing the agency's comments. The dd cfDNA kitted test, if authorized, would give transplant centers an in-house alternative to send-out testing—a shift that could reshape the molecular diagnostics market in transplantation.

Market Tailwinds and Pricing Power

Beyond the regulatory runway, IMDX is benefiting from an expanding reimbursement landscape. The recent MolDX LCD (Local Coverage Determination) raised surveillance frequency from 8 to 14 tests in the first three years post‑kidney transplant. CFO Andrea James was explicit about the impact: “We believe that Medicare's higher reimbursed testing frequency is favorable to our previously stated $2 billion total addressable market for kitted transplanted organ testing.” — Andrea James, Chief Financial Officer or Head of Investor Relations · 2026-08-10 That testing frequency expansion is a direct lever on the TAM, which is built on a conservative 2 tests per year per kidney recipient. As frequency climbs, so does the addressable market. Pricing power is another theme this quarter. Management believes the combination of high reimbursement and a lack of substitutes gives them an edge. As James explained, “Remember that our pricing power is tied to our reimbursement, and that remains true of whoever is running the test.” — Andrea James, Chief Financial Officer or Head of Investor Relations · 2026-08-10 That's an important point: even if reference labs demand volume discounts, the reimbursement floor protects pricing. The pricing power is further buttressed by the company's head-to-head data, which shows clinical equivalence to central-lab tests. Josh Riggs added, “We believe that we are about 2 years ahead with regard to kitted product development among competitors.” — Joshua Riggs, Chief Executive Officer · 2026-08-10 That lead time, combined with the fact that over half of the top-10 U.S. transplant centers are already working with the company through trials or the registry, positions IMDX as the early mover in a market that's suddenly looking at much more frequent testing.

Cash Runway and the Path to Breakeven

The story doesn't stop at regulatory approval—it's also about capital efficiency. IMDX guided cash burn to approximately $8 million per quarter in the second half of 2026, up from the prior $6 million expectation. The increase reflects the cost of completing the regulatory review process, registry activities, and commercial launch preparations. However, management was clear that Q2 2026 cash burn of $10 million should be the high watermark. “We now expect to burn approximately $8 million per quarter in the second half of this year.” — Andrea James, Chief Financial Officer or Head of Investor Relations · 2026-08-10 The company has a lever beyond cost cuts: the Nashville lab can generate GraftAssureCore revenue at a reimbursable rate of $2,753 per result. As James noted, “Remember that we have a test that we can run out of our Nashville lab that's reimbursable at $2,753 per result.” — Andrea James, Chief Financial Officer or Head of Investor Relations · 2026-08-10 That's an immediate revenue stream that can offset some of the burn while the kitted product waits for authorization. On the balance sheet, cash runway stands at 3.7 quarters as of the latest filing, but management is actively exploring options to extend it. The investment in the GALACTIC registry is a key lever—it both generates near-term revenue and familiarizes centers with the technology, creating a ready-made adoption base upon approval.

We continue to expect modest revenue in the second half across laboratory services, research use?only kit sales and GraftAssureCore.
Andrea James, Chief Financial Officer or Head of Investor Relations · 2026-08-10

That statement from Andrea James underscores the transition: the company is no longer just a science project—it's building a commercial engine.

Europe: The Second Front

While the FDA is the primary focus, IMDX is also advancing its IVDR self-certification for the U.K., with a target to submit in the second half of this year. Chief Science Officer Ekke Schutz was optimistic: “We are still really planning to get this done in the second half of this year. And I think there's a very, very realistic trend that we can do it.” — Ekkehard Schutz, Regulatory Affairs or Clinical Affairs Executive · 2026-08-10 Europe has been historically slower on reimbursement, but Switzerland has begun paying for some of this testing, and tenders are emerging in Italy. The biggest catalyst, per management, would be approval of an anti-CD38 drug for routine use, which would create a clear clinical use case for donor-derived cell-free DNA monitoring. That's a theme we haven't seen in prior quarters—a more concrete timeline for Europe. Earlier, management had framed Europe as early days; now it's a near-term initiative.

Financial and Operational Context

From a fundamental perspective, IMDX remains pre-revenue at scale, but the cost structure is improving. Research and development expense ticked up to $5 million in Q2, but that's down 15% sequentially as the company reallocates spending from clinical trial execution to commercialization prep. R&D is still elevated relative to 2024 levels, but the trajectory is flattening as management tightens oversight. The company's cash runway, at 3.7 quarters per the latest filing, is short enough to keep the approval timeline front and center, but the guided burn reduction and the potential for GraftAssureCore revenue provide a bridge. Interestingly, the stock has already begun to price in a successful authorization: over the past 90 days, IMDX is up ~37% (though still down ~97% all-time) and recently hit a high of $6.55 in June before pulling back. The options market and investor interest are clearly watching the regulatory deadline.

What Changed?

Three things are materially different from last quarter: (1) the FDA interaction has moved from passive waiting to an active SIR meeting, signaling a final alignment phase; (2) the reimbursement landscape has become structurally more favorable, with the MolDX LCD now supporting higher testing frequency; and (3) management has explicitly shifted its narrative from "development" to "commercialization," with a specific cash burn plan and a growing registry that acts as a customer pipeline. In the prior call, Riggs said: “We expect that most of these centers that join in the registry are going to be kit customers for us long term.” — Joshua Riggs, Chief Executive Officer · 2026-05-13 That's now becoming a near-term reality as the registry gains traction and the FDA clock winds down. The company is essentially executing on the playbook it laid out a year ago, but with a sharper definition of the endgame. The total addressable market, possibly growing beyond $2 billion, combined with a antibody mediated rejection treatment landscape that rewards early detection, makes IMDX a name to watch in the diagnostic space. The next 6 to 12 months will be defining. If the FDA authorization arrives as guided, the company could be one of the first to offer a kitted dd-cfDNA test for transplant rejection, tapping into a market that is just beginning to understand the value of frequent, in-house monitoring.